Proton magnetic resonance spectroscopy study of dyskinesia patients

Movement Disorders

Volumn 22, Issue 7, 2007, Pages 957-962

  Kuznetsov, Yevgeniy ^a   Khiat, Abdesslem ^a   Blanchet, Pierre J ^a   Boulanger, Yvan ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Antidepressants; Brain metabolites; Magnetic resonance spectroscopy; Spontaneous oral dyskinesia; Tardive dyskinesia

Indexed keywords

ANTIDEPRESSANT AGENT; CHOLINE; CREATINE; GLUTAMIC ACID; GLUTAMINE; INOSITOL; LIPID; METOCLOPRAMIDE; N ACETYLASPARTIC ACID; NEUROLEPTIC AGENT; PHOSPHATIDYLCHOLINE;

ADULT; AGED; ARTICLE; CELL MEMBRANE; CHOLINE CREATINE RATIO; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DIAGNOSTIC IMAGING; DRUG EFFECT; DRUG INDUCED DISEASE; DYSKINESIA; FEMALE; FRANCE; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; LIPID METABOLISM; MALE; MEASUREMENT; METABOLITE; NEUROIMAGING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RISK FACTOR; TARDIVE DYSKINESIA;

AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; CHOLINE; CREATINE; DYSKINESIAS; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PROTONS;

EID: 34347217530     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21459     Document Type: Article

References (30)

1. Yassa R, Nair NPV, Jeste DV, editors. Neuroleptic-induced Movement Disorders: a comprehensive survey. New York: Cambridge University Press; 1997. 512 p.
2. Sachdev PS. The current status of tardive dyskinesia. Aust N Z J Psychiatry 2000;34:355-369.
3. Pourcher E, Baruch P, Bouchard RH, Filteau MJ, Bergeron D. Neuroleptics associated tardive dyskinesias in young people with psychoses. Br J Psychiatry 1995;166:768-772.
4. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. Psychopharmacol Suppl 1985; 2:72-78.
5. Woerner MG, Alvir JM, Saltz BL, Lieberman JA, Kane JM. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 1998;155:1521-1528.
6. Anonymous. Extrapyramidal effects of SSRI antidepressants. Prescrire Int 2001;10:118-119.
7. Yassa R, Camille Y, Belzile L. Tardive dyskinesia in the course of antidepressant therapy: a prevalence study and review of the literature. J Clin Psychopharmacol 1987;7:243-246.
8. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996;57:449-454.
9. Vandel P, Bonin B, Leveque E, Sechter D, Bizouard P. Tricyclic antidepressant-induced extrapyramidal side effects. Eur Neuropsychopharmacol 1997;7:207-212.
10. Gerber PE, Lynd LD. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother 1998;32:692-698.
11. Blanchet PJ, Abdillahi O, Beauvais C, Rompré PH, Lavigne GJ. Prevalence of spontaneous oral dyskinesia in the elderly: a reappraisal. Mov Disord 2004;19:892-896.
12. Mion CC, Andreasen NC, Arndt S, Swayze VW, II, Cohen GA. MRI abnormalities in tardive dyskinesia. Psychiatry Res 1991;40: 157-166.
13. Dalgalarrondo P, Gattaz WF. Basal ganglia abnormalities in tardive dyskinesia: possible relationship with duration of neuroleptic treatment. Eur Arch Psychiatry Clin Neurosci 1994; 244:272-277.
14. Brown KW, White T, Wardlaw JM, Walker N, Foley D. Caudate nucleus morphology in tardive dyskinesia. Br J Psychiatry 1996; 169:631-636.
15. Bartzokis G, Garber HJ, Marder SR, Olendorf WH. MRI in tardive dyskinesia: shortened left caudate T2. Biol Psychiatry 1990;28: 1027-1036.
16. McCreadie RG, Thara R, Padmavati R, Srinivasan TN, Jaipurkar SD. Structural brain differences between never-treated patients with schizophrenia, with and without dyskinesia, and normal control subjects: a magnetic resonance imaging study. Arch Gen Psychiatry 2002;59:332-336.
17. Buckley P, O'Callaghan E, Mulvany F, et al. Basal ganglia T2 relaxation times in schizophrenia: a quantitative magnetic resonance imaging study in relation to tardive dyskinesia. Psychiatry Res 1995;61:95-102.
18. Elkashef AM, Buchanan RW, Gellad F, Munson RC, Breier A. Basal ganglia pathology in schizophrenia and tardive dyskinesia: an MRI quantitative study. Am J Psychiatry 1994;151:752-755.
19. Ando K, Takei N, Matsumoto H, Iyo M, Isoda H, Mori N. Neural damage in the lenticular nucleus linked with tardive dyskinesia in schizophrenia: a preliminary study using proton magnetic resonance spectroscopy. Schizophr Res 2002;57:273-279.
20. Kim MO, Im IH, Choi CG, Lee MC. Proton spectroscopic findings in paroxysmal kinesigenic dyskinesia. Mov Disord 1998;13:570-575.
21. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30: 672-679.
22. Koller WC. Edentulous orodyskinesia. Ann Neurol 1983;13:97-99.
23. Wilkinson ID, Paley MNJ, Miszkiel KA, Hall-Craggs MA, Kendall BE, Chinn RJS, Harrison MJG. Cerebral volumes and spectroscopic proton metabolites on MR: is sex important? Magn Reson Imaging 1997;15:243-248.
24. Nagae-Poetscher LM, Bonekamp D, Barker PB, Brant LJ, Kaufmann WE, Horská A. Asymmetry and gender effect in functionally lateralized cortical regions: a proton MRS imaging study. J Magn Reson Imaging 2004;19:27-33.
25. Pouwels PJW, Frahm J. Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magn Reson Med 1998;39:53-60.
26. Kadota T, Horinouchi T, Kuroda C. Development and aging of the cerebrum: assessment with proton MR spectroscopy. AJNR Am J Neuradiol 2001;22:128-135.
27. 1H chemical shift imaging of the human brain at age 60-90 years reveals metabolic differences between women and men. Magn Reson Med 1999; 42:24-31.
28. 1H magnetic resonance spectroscopy in brain diseases. Brain Res Rev 2000;33: 380-389.
29. Grimm JW, Chapman MA, Zahm DS, See RE. Decreased choline acetyltransferase immunoreactivity in discrete striatal subregions following chronic haloperidol in rats. Synapse 2001; 39:51-57.
30. 3 receptor modulation of haloperidol-induced c-fos expression in the striatum and nucleus accumbens. Neuroscience 2002;112:427-438.